Explorer les evidences

Kenya introduced a quadrivalent HPV vaccine (GARDASIL-4) for ten-year-old girls in late 2019.

Kenyainfection à HPVobservé late 2019publié 2023VaccinePubMeddocument de 6 observations

4,46 ORDetection of aflatoxin was associated with a higher risk of persistent detection of HR-HPV types not included in the 9-valent HPV vaccine (OR = 4.46, 95% CI = 1.13–17.58, P = 0.032) in Kenyan women.

Kenyainfection à HPVpublié 2023BMC infectious diseasesPubMeddocument de 5 observations

21,9 %Of 14,227 women screened using self-sampling for HPV DNA testing, 3111 (21.9%) were HPV positive.

Kenyainfection à HPVpublié 2026BMC cancerPubMeddocument de 12 observations

52,1 %Of the 135 HPV-positive women who were notified of their results, 73 (52.1%) received cryotherapy.

Kenyainfection à HPVobservé 2018publié 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 7 observations

58,52 %Mono-infection was common, accounting for 58.52% of cases.

Kenyainfection à HPVpublié 2025European journal of cancer prevention : the official journal of the European Cancer PrevenPubMeddocument de 6 observations

62 %HPV awareness was 62.0% among mothers of adolescent girls in Western Kenya.

Kenyainfection à HPVpublié 2021The Pan African medical journalPubMeddocument de 5 observations

61 %The 9-valent Gardasil vaccine would have prevented 61.0% of HPV types observed in this population of gbMSM in Nairobi, Kenya.

Kenyainfection à HPVpublié 2023Cancer medicinePubMeddocument de 7 observations

12,5 %Each additional year of ART use reduced the likelihood of detection of HR-HPV by 10-15% among Kenyan women living with HIV.

Kenyainfection à HPV · VIH/sidapublié 2021International journal of STD & AIDSPubMeddocument de 5 observations

24,6 %Among 115 gbMSM in Nairobi, Kenya, HPV prevalence was 24.6% among those without HIV.

Kenyainfection à HPVpublié 2023Cancer medicinePubMeddocument de 7 observations

3,63 ORDetection of aflatoxin was associated with a higher risk of persistent detection of HR-HPV types (OR = 3.63, 95% CI = 1.30–10.13, P = 0.014) in Kenyan women.

Kenyainfection à HPVpublié 2023BMC infectious diseasesPubMeddocument de 5 observations

Women who screened HPV-positive were more likely to be HIV-positive (p < 0.001).

Kenyainfection à HPV · VIH/sidapublié 2022BMC women's healthPubMeddocument de 7 observations

3,03 ORDetection of aflatoxin was associated with a higher risk of persistent detection of any HPV type (OR = 3.03, 95% CI = 1.08–8.55, P = 0.036) in Kenyan women.

Kenyainfection à HPVpublié 2023BMC infectious diseasesPubMeddocument de 5 observations

80 %The rate of HPV seropositivity at 48 months was 80% for HPV-11.

Kenyainfection à HPVobservé 48 monthspublié 2021VaccinePubMeddocument de 7 observations

30 %During a national phone survey in Kenya, 30% of male respondents reported having a daughter vaccinated against HPV.

Kenyainfection à HPVpublié 2026Cancer epidemiology, biomarkers & prevention : a publication of the American Association fPubMeddocument de 5 observations

2 297 womenCommunity health campaigns reached 2297 women aged 25–65 years in six communities in rural Western Kenya.

Kenyainfection à HPVpublié 2020BMJ openPubMeddocument de 4 observations

51,3 %Among 115 gbMSM in Nairobi, Kenya, overall HPV prevalence was 51.3%.

Kenyainfection à HPVpublié 2023Cancer medicinePubMeddocument de 7 observations

66,6 %HPV genotyping showed predominance of other high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) at 66.6% positivity.

Kenyainfection à HPVpublié 2026BMC cancerPubMeddocument de 12 observations

18,6 %Of the 750 women included in the study, 140 (18.6%) tested positive for HPV.

Kenyainfection à HPVobservé 2018publié 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 7 observations

37,1 USDThe mean cost per woman screened through home-based testing was $37.1.

Kenyainfection à HPVpublié 2020BMJ openPubMeddocument de 4 observations

0,2 fractionOne-fifth of respondents in Kenya had experienced, or anticipated experiencing, challenges accessing HPV vaccination services.

Kenyainfection à HPVobservé 2022publié 2024VaccinePubMeddocument de 2 observations

83,7 %Among 98 HPV-positive cervical samples, 83.7% (82/98) had high-risk (HR) HPV genotypes.

Kenyainfection à HPVpublié 2022BMC infectious diseasesPubMeddocument de 4 observations

37,7 USDThe mean cost per woman screened through community health campaigns was $37.7.

Kenyainfection à HPVpublié 2020BMJ openPubMeddocument de 4 observations

38,2 %38.2% of parents/caregivers in Kenya reported that age-eligible girl(s) in their household had received any doses of the HPV vaccine.

Kenyainfection à HPVobservé 2022publié 2024VaccinePubMeddocument de 2 observations

22,8 %The HPV positivity rate in the pilot study was 22.8% (1027 out of 4500).

Kenyainfection à HPVpublié 2023PloS onePubMeddocument de 16 observations

49,6 %Nearly half of the women who tested HPV positive (n = 1540; 49.6%) were eligible for rescreening using VIA.

Kenyainfection à HPVpublié 2026BMC cancerPubMeddocument de 12 observations